InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,479.97
(
0.38%
)
US TECH 100
18,663.20
(
0.78%
)
Dow Jones
40,602.15
(
0.03%
)
Brent Oil
78.69
(
-2.35%
)
Bitcoin
67,049.39
(
-1.10%
)
Post# of 43146
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DonDonDonDon

Send PM Follow Ignore
Followers 25
Posts 2345
Boards Moderated 0
Alias Born 06/20/2020

DonDonDonDon

Re: None

Thursday, 04/28/2022 11:38:48 AM

Thursday, April 28, 2022 11:38:48 AM

Post# of 43146
The wait for data is brutal. But it will be worth it. The primary endpoint population of the ACTIV trial had 243% efficacy in the LIVE-AIR trial. No other Covid treatment at any stage comes close to that efficacy. And there is still no good treatment for newly hospitalized patients which is obviously a very important stage to treat. Lenzilumab is coming soon to a hospital near you.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up